A Study to Evaluate the Effectiveness and Safety of Oral OPS-2071 in Subjects With Crohn's Disease Showing Symptoms of Active Inflammation

Overview

About this study

The purpose of this study is to evaluate the effects, safety and how OPS-2071 (150, 300, or 600 mg twice a day [BID]) is as an add-on therapy in Crohn's disease who show symptoms of active inflammation despite being on ongoing treatment.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria: 

  • Male and female subjects between the ages of 18 and 70 years, inclusive.
  • Diagnosis of Crohn's disease localized in the ileum and/or colon, with active mucosal inflammation and visible lesion(s), documented by centrally read ileocolonoscopy and a Simple Endoscopic Score for Crohn's Disease (SES-CD) ≥ 6 (≥ 4 for isolated ileal disease). 
  • Subjects who do not have an optimal response (daily stool frequency > 3 and pain score > 1) to their current ongoing treatment of biologics (e.g., first anti-tumor necrosis factor-alpha [TNF-α] monoclonal antibody), immunosuppressants, low-dose steroids, or 5-aminosalicylic acid (5-ASA) formulations.
  • Subjects who are on stable Crohn's disease medications for at least 4 weeks. 
  • Subjects with a CDAI score between 180 and 450 points, inclusive.
  • Subjects who are willing and able to follow the trial protocol and have signed informed consent.

Exclusion Criteria: 

  • Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving IMP. 
  • Sexually active males or WOCBP who do not agree to practice 2 different methods of birth control or remain abstinent during the trial and for 30 days after the last dose of IMP. If employing birth control, 2 of the following precautions must be used: vasectomy, tubal ligation, vaginal diaphragm, intrauterine device, birth control pill, birth control implant, birth control depot injection, condom with spermicide, or sponge with spermicide. 
  • Subjects taking any nonsteroidal anti-inflammatory drugs that cannot be stopped or replaced.
  • Use of prednisone or prednisolone > 30 mg/day or budesonide > 9 mg/day within 4 weeks prior to screening; or intravenous steroids within 4 weeks prior to screening.
  • Subjects taking blood thinners. 
  • Subjects with bowel stenosis > 5 mm, fistula, or stoma; or with 2 or more bowel resections. 
  • Subjects with a history of upper gastrointestinal involvement of Crohn's disease or perianal Crohn's disease. 
  • Subjects with prior surgery that removed the ileocecal valve or resections that led to short bowel syndrome. 
  • Subjects with known existing aortic aneurysm, or who are at risk for an aortic aneurysm, such as subjects with peripheral atherosclerotic vascular diseases, uncontrolled hypertension, certain genetic conditions such as Marfan syndrome and Ehlers-Danlos syndrome, and elderly subjects (over the age of 70). 
  • Subjects with known or suspected (family history, unexplained syncope) long QT syndrome or QTcF > 470 msec for females or > 450 msec for males at baseline. 
  • Subjects with inadequate organ function, as follows:
    • Serum creatinine > 1.5 x the upper limit of normal (ULN);
    • Aspartate aminotransferase or alanine aminotransferase levels > 1.5 x ULN;
    • Total bilirubin > 1.5 x ULN; Elevated unconjugated bilirubin related to Gilbert's syndrome is allowed.
  • Use of antibiotics (e.g., metronidazole, rifaximin, tinidazole, ciprofloxacin, clarithromycin) within 15 days prior to screening or for greater than 2 months within the past year. A short course (maximum of 5 days) of antibiotics will be permitted during the trial, as needed, for indications other than Crohn's disease. 
  • Known hypersensitivity to quinolones or other significant adverse reaction to quinolones. 
  • Conditions or circumstances that could prevent completion of the trial according to the judgment of the investigator, including an uncontrolled comorbidity, heart condition, or dysfunction of any other organ; peripheral neuropathy; known arrhythmias, atrial fibrillation, or paroxysmal tachycardia; history of myasthenia gravis; history of drug or alcohol abuse, mental illness, or noncompliance with treatments or visits; or known immune-deficiency. 
  • HIV infection, viral hepatitis, prior organ transplant, or malignant disease that is not in remission for at least 3 years, with the exception of basal cell carcinoma. 
  • Subjects who have used any investigational drug within 2 months prior to screening. 
  • Blood donation in the last 2 months. 
  • Use of inhibitors of UGT1A1 and UGT1A9 (e.g., Silybin, diclofenac, mycophenolic acid, efavirenz, regorafenib) and BCRP (eg, Estrone, 17β-estradiol, flavonoids, herb extracts, gefitinib, imatinib, tamoxifen, novobiocin, nelfinavir, ritonavir, dipyridamole, fumitremorgin C, Ko143, cyclosporine, curcumin, eltrombopag, omeprazole, ivermectin). 
  • Subjects with a history of treatment failure with 2 or more biologics. 
  • Subjects with risk factors for tendon rupture (i.e., psoriasis, ankylosing spondylitis, competitive athletes, renal failure, diabetes mellitus) or who have a history of tendon rupture and/or ongoing tendinopathy.
  • Subjects with systolic blood pressure > 150 mmHg or diastolic blood pressure > 90 mmHg.
  • Subjects taking quinidine, procainamide, disopyramide, encainide, flecainide, sotalol, amiodarone, ibutilide, dronedarone, or propafenone.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Darrell Pardi, M.D.

Open for enrollment

Contact information:

Patricia Kammer CCRP

(507)538-1827

Kammer.Patricia@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available